多发性骨髓瘤患者附肢骨骼骨髓异常预后意义
研究纳入196例新诊断症状性多发性骨髓瘤患者,初诊时行低剂量全身多排CT检查,按附肢骨骼骨髓模式分为脂肪型(36.3%)、局灶型(43.4%)和弥漫型(20.4%)。中位随访35.4个月,三组中位生存分别为未达到、56个月和38个月;多因素分析显示弥漫型是PFS独立预测因子(HR 1.92),局灶型和弥漫型是OS独立预测因子(HR 2.51和4.12)。
要点
- 附肢骨骼骨髓异常与Durie-Salmon分期3期、修订国际分期系统3期、肌酐>2.0 mg/dL及骨髓浆细胞比例相关。
- 脂肪型、局灶型、弥漫型患者中位生存分别为未达到、56个月、38个月。
- 弥漫型是PFS独立预测因子(HR 1.92;95%CI 1.12-3.31;P=.018),局灶型和弥漫型是OS独立预测因子(HR 2.51和4.12)。
核心结论
- 低剂量全身多排CT检测的附肢骨骼骨髓异常与不良预后相关,且独立于其他临床变量。
研究设计与样本
- 研究纳入196例新诊断症状性多发性骨髓瘤患者,初诊时行低剂量全身多排CT检查,按附肢骨骼骨髓模式分为脂肪型、局灶型和弥漫型三组。
主要发现
- 附肢骨骼骨髓异常与Durie-Salmon分期3期、修订国际分期系统3期、肌酐>2.0 mg/dL及骨髓浆细胞比例相关。
- 中位随访35.4个月,脂肪型、局灶型和弥漫型患者的中位生存分别为未达到、56个月和38个月。
- 单因素分析显示总生存与年龄、Durie-Salmon分期3期、肌酐>2.0 mg/dL、不适合自体干细胞移植以及局灶型和弥漫型模式相关。
- 多因素分析显示年龄和弥漫型模式是PFS独立预测因子(HR 1.92;95%CI 1.12-3.31;P=.018)。
- 年龄、局灶型(HR 2.51;95%CI 1.14-5.56;P=.023)和弥漫型(HR 4.12;95%CI 1.74-9.77;P=.001)模式也是OS独立预测因子。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aimed to determine the clinical and prognostic significance of medullary abnormalities detected by low-dose whole-body multidetector computed tomography (MDCT) in the appendicular skeleton (AS) of patients with newly diagnosed symptomatic multiple myeloma (MM). One hundred ninety-six patients underwent low-dose whole-body MDCT as an initial workup. Patients were categorized into 3 groups based on the medullary pattern of the AS: fatty (36.3%), focal (43.4%), and diffuse (20.4%). Medullary abnormalities were associated with Durie-Salmon and revised International Scoring System stage 3, creatinine levels >2.0 mg/dL, and the proportion of bone marrow plasma cells. The median follow-up was 35.4 months. Patients with fatty, focal, and diffuse patterns had a median survival of not reached, 56 months, and 38 months, respectively. Overall survival (OS) was associated with age, Durie-Salmon stage 3, creatinine levels >2.0 mg/dL, ineligibility for autologous stem cell transplantation, and focal and diffuse patterns on univariate analysis. Multivariate analysis showed that age and diffuse pattern (hazard ratio [HR], 1.92; 95% confidence interval [CI], 1.12-3.31; P = .018) were independent predictors of progression-free survival. Age and focal (HR, 2.51; 95% CI, 1.14-5.56; P = .023) and diffuse (HR, 4.12; 95% CI, 1.74-9.77; P = .001) patterns were also independent predictors of OS. The addition of marrow pattern to preexisting risk factors was associated with a net reclassification improvement for predicting OS (to 0.37, P = .015). Medullary abnormalities in the AS (detected by low-dose whole-body MDCT) are associated with a poor prognosis, independent of other clinical variables.
引用
- Matsue K, Kobayashi H, Matsue Y, et al. Prognostic significance of bone marrow abnormalities in the appendicular skeleton of patients with multiple myeloma. Blood Adv. 2018. PMID: 29739774. doi:10.1182/bloodadvances.2017014720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。